Chronic lymphocytic leukaemia
Not recruitingStudy on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease
Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease
- Disease:Chronic lymphocytic leukaemia
- Substances:IbrutinibObinutuzumab+1
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Ibrutinib
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting









